Director Chris Mahai buys 527 abrdn Life Sciences (NYSE: HQL) shares

Rhea-AI Filing Summary

abrdn Life Sciences Investors director Chris LaVictoire Mahai purchased 527 shares of Common Stock on 2026-07-16 in an open-market or private transaction at $19.92 per share. After this trade, Mahai directly owns 527 shares of HQL. The filing indicates the transaction was not under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 527 shares

Net Buy 1 txn

Insider Mahai Chris LaVictoire

Role Director

Bought 527 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	527	$19.92	$10K

Holdings After Transaction: Common Stock — 527 shares (Direct)

Key Figures

Shares purchased: 527.0000 shares Purchase price: $19.9200 per share Shares owned after transaction: 527.0000 shares +1 more

4 metrics

Shares purchased 527.0000 shares Common Stock purchased on 2026-07-16

Purchase price $19.9200 per share Per-share price for the 2026-07-16 Common Stock purchase

Shares owned after transaction 527.0000 shares Direct Common Stock holdings after reported purchase

Net buy/sell shares 527 shares Net shares bought across all reported transactions in this filing

Key Terms

Rule 10b5-1 trading plan, open market or private transaction, direct ownership

3 terms

Rule 10b5-1 trading plan financial

"The filing indicates the transaction was not under a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"transaction_code_description: Purchase in open market or private transaction"

direct ownership financial

"ownership_type: direct, indicating direct ownership of the shares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/20/2026 - 02:36 PM Accepted by SEC EDGAR 07/20/2026 - 02:36 PM Learn about SEC filing dates

FAQ

What insider transaction did HQL report for Chris LaVictoire Mahai?

abrdn Life Sciences Investors reported that director Chris LaVictoire Mahai bought 527 shares of HQL Common Stock on 2026-07-16. The purchase was reported as an open-market or private transaction and is Mahai’s only transaction in this filing.

How many HQL shares did Mahai buy and at what price?

Mahai purchased 527 shares of abrdn Life Sciences Investors at a reported price of $19.92 per share. The price reflects a purchase in an open-market or private transaction as characterized in the filing’s transaction code description.

What are Chris LaVictoire Mahai’s HQL holdings after this Form 4 trade?

Following the reported transaction, Mahai directly owns 527 shares of HQL Common Stock. The filing lists this figure as the total shares following the transaction, and all of these holdings are reported as being held directly rather than indirectly.

Was Mahai’s HQL share purchase under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmed, indicating the reported purchase was not made under a Rule 10b5-1 trading plan. This suggests the transaction was not executed pursuant to a pre-arranged trading program.

Is Mahai’s HQL transaction classified as a buy or sell on the Form 4?

The Form 4 classifies Mahai’s activity as a purchase, with the transaction direction recorded as buy and the acquired/disposed code shown as “A” for acquired. No sales or other dispositions of HQL shares are reported in this filing.

Is Mahai’s ownership in HQL direct or indirect after this transaction?

The filing identifies Mahai’s post-transaction position as direct ownership of 527 shares. The ownership code is listed as “D”, meaning the shares are held directly rather than through an intermediary entity such as a trust, fund, or family vehicle.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahai Chris LaVictoire

(Last) (First) (Middle)

C/O ABRDN

1900 MARKET STREET, SUITE 200

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
abrdn Life Sciences Investors [ HQL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2026		P		527	A	$19.92	527	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Robert Stieger, by POA from Reporting Person	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)